V
Vijayalakshmi Chandrasekaran
Researcher at GlaxoSmithKline
Publications - 16
Citations - 424
Vijayalakshmi Chandrasekaran is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Vaccination & Reactogenicity. The author has an hindex of 9, co-authored 15 publications receiving 386 citations.
Papers
More filters
Journal ArticleDOI
Vaccine for Prevention of Mild and Moderate-to-Severe Influenza in Children
Varsha K. Jain,Luis Rivera,Khalequ Zaman,Roberto A. Espos,Chukiat Sirivichayakul,Beatriz P. Quiambao,Doris Maribel Rivera-Medina,Pirunghul Kerdpanich,Mehmet Ceyhan,Ener Cagri Dinleyici,Alejandro Cravioto,Mohammed Yunus,Pornthep Chanthavanich,Kriengsak Limkittikul,Zafer Kurugöl,Emre Alhan,Adrian Caplanusi,Serge Durviaux,Philippe Boutet,Opokua Ofori-Anyinam,Vijayalakshmi Chandrasekaran,Ghassan Dbaibo,Bruce L. Innis +22 more
TL;DR: The QIV was efficacious in preventing influenza in children and associated with reduced risks of a body temperature above 39°C and lower respiratory tract illness, as compared with the control vaccine, in the per-protocol cohort.
Journal ArticleDOI
Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial
Juan Carlos Tinoco,Noris Pavía-Ruz,Aurelio Cruz-Valdez,Carlos Aranza Doniz,Vijayalakshmi Chandrasekaran,Walthère Dewé,Aixue Liu,Bruce L. Innis,Varsha K. Jain +8 more
TL;DR: Immunogenicity of QIV lots was consistent, QIV was superior to TIV for the alternate B-lineage strain, andQIV was non-inferior versus TIVs for shared strains (A/H1N1, A/H3N2, B-strain).
Journal ArticleDOI
Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
Joanne M. Langley,Alfonso Carmona Martinez,Archana Chatterjee,Scott A. Halperin,Shelly A. McNeil,Shelly A. McNeil,Keith S. Reisinger,Naresh Aggarwal,Li-Min Huang,Ching-Tien Peng,José Garcia-Sicilia,Ignacio Salamanca de la Cueva,Fernando Cabañas,Consuelo Treviño-Garza,Miguel Angel Rodríguez-Weber,Manuel de la O,Vijayalakshmi Chandrasekaran,Walthère Dewé,Aixue Liu,Bruce L. Innis,Varsha K. Jain +20 more
TL;DR: QIV elicited superior HI responses to the added B strains compared to TIV controls, potentially improving its effectiveness against influenza B and had an acceptable safety profile relative to Tivs.
Journal ArticleDOI
Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
Joanne M. Langley,Long Wang,Naresh Aggarwal,Agustin Bueso,Vijayalakshmi Chandrasekaran,Luis Cousin,Scott A. Halperin,Ping Li,Aixue Liu,Shelly A. McNeil,Lourdes Peña Mendez,Luis Rivera,Bruce L. Innis,Varsha K. Jain +13 more
TL;DR: In children aged 6 to 35 months, a QIV has superior immunogenicity for the added B strain and acceptable immunogenicicity for shared strains, with no notable difference in reactogenicity and safety when compared to a TIV.
Journal ArticleDOI
Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial
Long Wang,Vijayalakshmi Chandrasekaran,Joseph B. Domachowske,Ping Li,Bruce L. Innis,Varsha K. Jain +5 more
TL;DR: The authors compared inactivated seasonal quadrivalent influenza vaccines (QIV) versus TIV (15 and 7.5 μg hemagglutinin [HA] for each influenza strain, respectively) in a phase II randomized (1 : 1), observer-blind trial in US children 6-35 months of age (identifier NCT01974895).